You Position: Home > Paper
Dasatinib monotherapy for chronic myeloid leukemia in blast crisis: report of one case and review of literature
( views:87, downloads:72 )
- Author:
- No author available
- Journal Title:
- Journal of Leukemia & Lymphoma
- Issue:
- 12
- DOI:
- 10.3760/cma.j.issn.1009-9921.2019.12.015
- Key Word:
- 白血病,髓系,慢性;BCR-ABL阳性;急髓变;药物疗法;达沙替尼
Abstract： 目的 观察达沙替尼单药治疗慢性粒细胞白血病(CML)急髓变的疗效及安全性.方法 回顾性分析东莞市人民医院1例应用达沙替尼单药治疗的CML急髓变患者的临床经过,并复习相关文献.结果 患者骨髓检查提示CML急髓变,同时伴随附加染色体核型异常,但BCR-ABL1激酶区突变阴性,坚持服用达沙替尼(100 mg/d)靶向治疗,并每月动态监测BCR-ABLIS基因水平.患者BCR-ABLIS基因水平逐渐下降,骨髓细胞学提示完全缓解,流式免疫微小残留转阴.治疗期间除可控的骨髓抑制及轻度肝损伤外,未出现其他严重不良反应.结论 CML急髓变后可根据患者激酶区突变情况选取不同的治疗策略,如无激酶区突变,达沙替尼单药治疗患者易耐受、安全有效,可作为优先治疗方案,但治疗期间需密切监测BCR-ABLIS基因水平,符合移植条件的患者仍应争取异基因造血干细胞移植以改善长期预后.
- [1]李明会,魏旭东,尹青松,等.达沙替尼一线治疗慢性粒细胞白血病进展期及Ph+急性淋巴细胞白血病三例并文献复习[J].2013,(10).
- [2]Oliver,Ottmann,Giuseppe,Saglio,Jane F,Apperley,etc.Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.[J].2018,8(9).
- [3]Elias Jabbour,Jorge Cortes,Hagop Kantarjian.Long‐term outcomes in the second‐line treatment of chronic myeloid leukemia[J].2011,117(5).
- [4]Cortes J,Kim D-W,Raffoux E,etc.Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase[J].2008,22(12).
- [5]Kornblau S,Thomas D,O'Brien S,etc.Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.[J].2009,115(11).
- [6]D. Milojkovic,J. F. Apperley,G. Gerrard,etc.Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients[J].2011,119(8).
- [7]Hanfstein B,Müller M C,Hehlmann R,etc.Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)[J].2012,26(9).
- [8]Khorashad JS,Kaeda J,Reid AG,etc.Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.[J].2008,26(20).
- [9]Hochhaus A,Baccarani M,Deininger M,etc.Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib[J].2008,22(6).
- [10]Alois, Gratwohl,Ronald, Brand,Jane, Apperley,etc.Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplan[J].2006,91(4).
- [11]Hochhaus, Andreas,Larson, Richard A.,Guilhot, Francois,etc.Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia[J].2017,376(10).
- [12]Sexl V,Fajmann S,Herrmann H,etc.High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.[J].2011,117(12).
- [13]Luatti,S.,Castagnetti,F.,Marzocchi,G.,etc.Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis[J].2012,120(4).
- [14]Jorge, Cortes,Philippe, Rousselot,Dong-Wook, Kim,etc.Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.[J].2007,109(8).